Lonnel Coats

Lonnel Coats discloses dealings in 3 companies, chiefly Lexicon Pharmaceuticals, Inc., Blueprint Medicines Corp and Mineralys Therapeutics, Inc. In total, 81 filings cover trades dated from 29 February 2016 to 19 October 2026.

On the open market, the record shows 45 purchases worth €954k and 3 sales worth €741k. On balance, insiders were net buyers of €212k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 12 share grants and 20 option exercises.

A typical purchase (the median) is worth €6,351. 42 out of 43 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 43 purchases show a median change of -19.9%, with the price up in 37% of them. This is a record of the past, not a forecast.

Most recently, on 20 October 2026, the filings show a share grant in Mineralys Therapeutics, Inc. The clock since the last published purchase (17 November 2023) now reads 1,069 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.